Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes.

R Bucala; K J Tracey; A Cerami

doi:10.1172/JCI115014

Laboratory of Medical Biochemistry, Rockefeller University, New York 10021.

Find articles by Bucala, R. in: PubMed | Google Scholar

Laboratory of Medical Biochemistry, Rockefeller University, New York 10021.

Find articles by Tracey, K. in: PubMed | Google Scholar

Laboratory of Medical Biochemistry, Rockefeller University, New York 10021.

Find articles by Cerami, A. in: PubMed | Google Scholar

Published in Volume 87, Issue 2 on February 1, 1991
J Clin Invest. 1991;87(2):432–438. https://doi.org/10.1172/JCI115014.
© 1991 The American Society for Clinical Investigation

Published February 1, 1991 - Version history

Nitric oxide (an endothelium-derived relaxing factor) induces smooth muscle relaxation and is an important mediator in the regulation of vascular tone. Advanced glycosylation end products, the glucose-derived moieties that form nonenzymatically and accumulate on long-lived tissue proteins, have been implicated in many of the complications of diabetes and normal aging. We demonstrate that advanced glycosylation products quench nitric oxide activity in vitro and in vivo. Acceleration of the advanced glycosylation process in vivo results in a time-dependent impairment in endothelium-dependent relaxation. Inhibition of advanced glycosylation with aminoguanidine prevents nitric oxide quenching, and ameliorates the vasodilatory impairment. These results implicate advanced glycosylation products as important modulators of nitric oxide activity and endothelium-dependent relaxation.